Medistim Forecast, price target & analysts
Medistim Target price 2025 - Analyst rating & recommendation
Medistim Classifications & Recommendation:
Medistim Price Target
| Target Price | NOK172.00 |
| Price | NOK170.00 |
| Potential |
1.18%
register free of charge
|
| Number of Estimates | 1 |
|
1 Analyst has issued a Medistim price target 2026.
The average Medistim target price is NOK172.00.
This is
1.18%
register free of charge
|
|
| A rating was issued by 1 analysts: 0 Analysts recommend Medistim to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Medistim stock has an average upside potential 2026 of
1.18%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million NOK | 562.60 | 602.06 |
| 7.96% | 7.01% | |
| EBITDA Margin | 27.66% | 25.66% |
| 3.83% | 7.22% |
1 Analyst has issued a sales forecast Medistim 2025 . The average Medistim sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Medistim 2025 . The average Medistim EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share NOK | 5.67 | 5.73 |
| 0.18% | 1.06% | |
| P/E | 30.71 | |
| EV/Sales | 5.10 |
1 Analysts have issued a Medistim forecast for earnings per share. The average Medistim EPS is
This results in the following potential growth metrics and future valuations:
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
